Grant of options - Director's dealing
Released : Aug 31, 2017
Tiziana Life Sciences PLC
("Tiziana" or the "Company")
Grant of options - Director's dealing
Dr Kunwar Shailubhai, the Company's Chief Executive Officer and Chief Scientific Officer, has been awarded options over 400,000 ordinary shares in the capital of the Company. The options are exercisable at a price of
A further 168,000 options over ordinary shares in the capital of the Company were granted by the Company to staff members on the same terms and on the same date.
The Company's issued share capital comprises 123,827,938 ordinary shares of 3p each.
Including the grants noted above, the Company has granted options over a total of 10,717,403 ordinary shares of which 4,752,500 are vested at exercise prices between 15p and
Therefore the fully diluted issued share capital of the Company is 138,784,920 ordinary shares (assuming all options and warrants, vested and unvested, exercised and exercisable, were converted).
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Contacts:
Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder
|
+44 (0)20 7493 2853 |
Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner / Richard Nash
|
+44 (0)20 7213 0880 |
Beaufort Securities Limited (Broker) Saif Janjua
|
+44 (0)20 7382 8300 |
FTI Consulting Simon |
+44 (0)20 3727 1000 |
About Tiziana Life Sciences
Tiziana Life Sciences plc is a
For more information go to http://www.tizianalifesciences.com
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
||||||||
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||
a. |
Name |
Dr Kunwar Shailubhai |
||||||
2 |
Reason for notification |
|
||||||
a. |
Position/Status |
Chief Executive Officer |
||||||
b. |
Initial notification/ Amendment |
31 August 2017 |
||||||
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
a. |
Name |
Tiziana Life Sciences plc |
||||||
b. |
LEI |
|
||||||
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
a. |
Description of the financial instrument, type of instrument
Identification Code |
Option
GB00BKWNZY55 |
||||||
b. |
Nature of the transaction |
Grant of options |
||||||
c. |
Price(s) and volume(s) |
|
|
|
|
|
||
|
Price(s) |
Volume(s) |
|
|||||
159.5p |
400,000 |
|
||||||
|
||||||||
d. |
Aggregated information
- Aggregated Volume
- Price |
400,000
159.5p |
||||||
e. |
Date of the transaction |
31 August 2017 |
||||||
f. |
Place of the transaction |
XLON |
||||||
This information is provided by RNS